Saturday, November 27, 2021
HomeEditor's PickSLIT associated with significant desensitisation in peanut-allergic toddlers

SLIT associated with significant desensitisation in peanut-allergic toddlers

Peanut sublingual immunotherapy (SLIT) was associated with significant desensitisation in toddlers, ages one- to four-years, with no safety issues, a US randomised trial showed.

During the placebo-controlled trial, cumulative tolerated dose in the peanut SLIT group increased to 4,333 mg of peanut protein versus 143 mg in the placebo group (P<0.0001), according to Dr Edwin Kim, of the University of North Carolina Food Allergy Initiative in Chapel Hill.

The treatment effect achieved with peanut SLIT was stronger than that previously reported in studies involving older children and it tended to last longer, Kim said during his presentation at the American Academy of Allergy, Asthma & Immunology virtual meeting.

The study is among the first to examine peanut SLIT safety and efficacy in toddlers, and Kim is quoted as saying that as more children are introduced to allergic foods during infancy, very early identification of food sensitisation will become more common.

Peanut SLIT has been shown to be associated with varying degrees of sensitisation in earlier, small clinical trials, but those trials involved older children and even teenagers. The strongest desensitisation in these previous trials was observed in the youngest children, Kim said.

Kim's group included 50 children (average age 2.2 years) with food challenge-confirmed peanut sensitivity (positive peanut-specific IgE and skin prick test).

In the peanut SLIT group, 21 children were white and there were no Black children. In the placebo group, 23 children were white and there were two Black children. A total of 84% and 76% of the children had atopic dermatitis and 28% and 24% had asthma, respectively. The groups were similar across gender, peanut skin-prick tolerance, and double-blind peanut challenge.

Participants were randomised 1:1 to receive peanut SLIT at a daily maintenance dosage of 4-mg peanut protein versus placebo for 36 months. Desensitisation was assessed through double-blind, placebo-controlled food challenge (DBPCFC) to 4,333 mg of peanut protein. Sustained unresponsiveness, indicating desensitisation, was also assessed by DBPCFC 3 months after discontinuing peanut SLIT.

A total of 36 children (19 peanut SLIT; 17 placebo) completed the desensitisation DBPCFC.

Kim reported that 14 children in the peanut SLIT group passed the desensitisation DBPCFC, and 12 passed the sustained responsiveness DBPCFC versus 0 and 2 toddlers, respectively, in the placebo group.

Peanut skin-prick test decreased from 10 mm to 3.25 mm with peanut SLIT versus 11.5 mm to 12 mm with placebo (P<0.0001).

Out of approximately 20,000 total doses given, symptoms were associated with 1,031 peanut SLIT doses and 629 placebo doses. Oral itch, skin itch, and gastrointestinal symptoms were the most common symptoms, and no children required epinephrine.

Kim noted that peanut specific IgE and skin testing demonstrated immune modulation in parallel with the clinical responses seen in the trial.

"In this younger cohort, there was a higher percentage of patients demonstrating sustained unresponsiveness than previously reported with peanut SLIT, and also for a longer duration – 3 months in this case compared to 3 to 4 weeks in previous trials," he said.

SLIT therapy is administered using a dropper, and the treatment is placed under the tongue. It is intended to be held there for two minutes before swallowing. Kim said that full compliance with the two-minute recommendation probably did not occur with the study cohort.

 

 

Study details
Safety and efficacy of peanut sublingual immunotherapy in toddler-aged peanut-allergic children

Edwin Kim, J Andrew Bird, Lauren Herlihy, Amy Arneson, Deanna Hamilton, Ping Ye, Michael Kulis, A Wesley Burks

Published in The Journal of Allergy and Clinical Immunology on 1 February 2021

Abstract
Rationale
Studies of peanut sublingual immunotherapy (PNSLIT) have suggested improving desensitization with younger age of initiation. The safety and efficacy of PNSLIT has not been described in toddler-aged children.
Methods
Food challenge confirmed peanut-allergic children ages 1-4 years with positive peanut-specific IgE and skin prick test (SPT) were randomized 1:1 to receive PNSLIT at a daily maintenance dose of 4mg peanut protein versus placebo for 36 months. Desensitization was assessed by double-blind, placebo-controlled food challenge (DBPCFC) to 4333mg of peanut protein. Sustained unresponsiveness (SU) was assessed by identical DBPCFC after discontinuing PNSLIT for 3 months. Dosing compliance and side effects were recorded on home diaries.
Results
Fifty participants (median age 2.2 years) were randomized at 2 academic centers. The groups were similar across gender, race, ethnicity, atopic history, peanut SPT, and qualifying DBPCFC. Of 36 participants (19 PNSLIT, 17 placebo) completing the desensitization DBPCFC, cumulative tolerated dose increased from median 143mg to 4443mg in the PNSLIT group and 43mg to 143mg in the placebo group (p<0.0001). Fourteen PNSLIT participants passed the desensitization DBPCFC and 12 passed the SU DBPCFC compared to 0 desensitization and 2 SU in the placebo group. Peanut SPT decreased from 10mm to 3.25mm PNSLIT versus 11.5mm to 12mm with placebo (P<0.0001). Symptoms were reported with 1031 PNSLIT doses versus 629 placebo doses with over 20000 doses taken.
Conclusions
Significant desensitization was observed with PNSLIT in peanut-allergic toddlers when compared to placebo with a strong potential for SU. PNSLIT may be a promising treatment option for early intervention in peanut allergy.

 

[link url="https://www.jacionline.org/article/S0091-6749(20)31769-3/fulltext"]The Journal of Allergy and Clinical Immunology (Restricted access)[/link]

 

 

See also MedicalBrief archives:

[link url="https://www.medicalbrief.co.za/archives/sublingual-immunotherapy-effective-and-safety-treatment-for-peanut-allergy/"]Sublingual immunotherapy effective and safe treatment for peanut allergy[/link]

 

[link url="https://www.medicalbrief.co.za/archives/approval-first-medical-tx-children-peanut-allergies-2019/"]Approval for first medical Tx for children with peanut allergies in 2019[/link]

 

[link url="https://www.medicalbrief.co.za/archives/peanut-allergy-may-cured-probiotics/"]Peanut allergy may be cured with probiotics and peanut oral immunotherapy[/link]

 

[link url="https://www.medicalbrief.co.za/archives/new-us-guidelines-support-infant-exposure-peanuts/"]New US guidelines support infant exposure to peanuts[/link]

 

[link url="https://www.medicalbrief.co.za/archives/peanut-allergy-protections-persists-after-a-year/"]Peanut allergy protections persists after a year[/link]

 

[link url="https://www.medicalbrief.co.za/archives/peanut-allergies-can-be-reversed-study/"]Peanut allergies can be reversed – study[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required